ClinicalTrials.gg
CompletedNCT05357820Updated Nov 21, 2024

A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK

A Phase 1 interventional study of AB-106, Itraconazole and AB-106, Rifampicin in Solid Tumor, sponsored by Nuvation Bio Inc.. Completed at 1 site in China. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by Nuvation Bio Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

AB-106-C110 is China-only study, for investigating the drug interaction between AB-106 and CYP3A4 inhibitor (Itraconazole)/CYP3A4 inducer (Rifampin)(n=56)

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Nuvation Bio Inc. is the lead sponsor of 19 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject is willing to give written .
  2. The subject is capable to communicate well with investigator and comply with comply with protocol throughout the study.
  3. Aged between 18 to 55 at giving written informed consent.
  4. Chinese male healthy subjects (No clinical abnormality by medical history query, physical examination, vital signs, 12 lead and clinical laboratory test)
  5. Body weight greater than 50.0 kg, and between 19 and 26 kg/m2, inclusive.
  6. For fertile males, agree to use effective methods during the study intervention period and for at least 90 days after the last dose of drug, and agree not to donate sperm during this period.

Exclusion criteria

Exclusion Criteria:

  1. Any presence or history of hematology, nephrology, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, mental, neurological, or allergic diseases (including drug allergy, but not including untreated, asymptomatic seasonal allergies when administered).
  2. Any clinically significant laboratory abnormality (hematology, biochemistry [fasting], coagulation, thyroid function, urinalysis.)
  3. systolic blood pressure (SBP) \< 90 mmHg or ≥140 mmHg, diastolic blood pressure (DBP) \< 50 mmHg or ≥ 90 mmHg, and clinically significant abnormality based on the judgment of investigators
  4. Any presence or history of eye disease in whom the risk is increased by the participation to the study or treatment with drug in the opinion of the investigator, such as glaucoma, retinal detachment, vitreous turbidity, and moths.
  5. The 12-lead showed > 450 milliseconds (msec) or QRS interval > 120 msec. If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times, and the average of 3 QTcF or QRS values should be used to determine subject's eligibility.
  6. Fever within 5 days before the administration.
  7. Active virus (HBV) surface antigen, virus antibody (HCV Ab), (HIV) or treponema pallidum (TP) antibody
  8. Within 28 days prior to the first dose of study treatment, use of food or drugs that are known potent inhibitors including (but not limited to) atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, aceto-eandomycin, voriconazole, grapefruit, grapefruit juice, grapefruit, citrus fruits or grapes Pomelo mixed species; or potent CYP3A4 inducers including (but not limited to) carbamazepine, phenobarbital, phenytoin, rifabutin, and rifampin and St. John's wort; or CYP3A4 substrates with narrow therapeutic window including (but not limited to)dihydroergotamine, ergotamine, pimozide, astemizole, cisapride, and terfenadine.
  9. Chinese herbal medicine or tonic must be withdrawn at least 28 days prior to the first dose of study treatment; Any clinical study drug is prohibited within 3 months or 5 half-lives prior to the first dose of investigational drug; Any prescription/over-the-counter drug/dietary supplement is prohibited within 14 days or 5 half-lives prior to the first dose of investigational drug; as an exception, acetaminophen/paracetamol can be used at a dose of 1 g/day.
  10. Vaccinated with live or attenuated vaccine within 28 days prior to the first dose of study treatment
  11. Subject is unwilling to withdraw foods containing caffeine or purines (such as coffee, tea, cola, chocolate) from 48h before first dose to finishing the last PK sample collection.
  12. Alcohol intake is greater than 14 units/week (1 unit of alcohol is equivalent to 360 mL of beer, or 150 mL of wine, or 45 mL of baijiu), or subject is unwilling to withdraw alcohol from 48h before first dose to finishing the last PK sample collection.
  13. Smoking more than 5 cigarette per day, or subject is unwilling to withdraw nicotine from 48h before first dose to finishing the last PK sample collection.
  14. Any drug abuse, or taking any soft drug (such as marijuana) or hard drugs (heroin, cocaine, etc.) from 1 year before and during the study period.
  15. Any significant surgical history within 6 months prior to the first dose of study treatment.
  16. Blood donation or blood loss ≥ 400 mL within 3 months or ≥ 200 mL within 1 month prior to the first dose of study treatment.
  17. Presence of gastrointestinal, liver, kidney disease or other diseases or sequelae that are known to interfere with drug absorption, distribution, metabolism, or excretion. With a history of sensitivity to heparin or heparin-induced thrombocytopenia
  18. Unwilling or incapable to follow the lifestyle standard described in the protocol.
  19. Staff members of any institution affiliated with the clinical site and their immediate family members. Immediate family members refer to persons with blood or legal relationship, including spouses, children, parents, and siblings.
  20. Ineligible to participate in the study based on the judgement of investigators
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Itraconazole cohort

    Drug: AB-106, Itraconazole

  • Experimental
    Rifampicin cohort

    Drug: AB-106, Rifampicin

Interventions

  • DrugAB-106, Itraconazole

    Drug pages: Taletrectinib · Itraconazole

    single dose AB-106 at Day1, Itraconazole QD at Day14\~Day28, single dose AB-106 at Day17

  • DrugAB-106, Rifampicin

    Drug pages: Taletrectinib · Rifampin

    single dose AB-106 at Day1, Itraconazole QD at Day14\~Day32, single dose AB-106 at Day21

06

What researchers measure

Primary outcomes

  1. AB-106 PK Exposure Parameters

    Peak Plasma Concentration (Cmax)

    Time frame: 29 days

  2. AB-106 PK Exposure Parameters

    Area under the plasma concentration versus time curve (AUC)

    Time frame: 29 days

Secondary outcomes

  1. AB-106 PK Parameters

    Time to drug peak plasma concentration (Tmax)

    Time frame: 29 days

  2. AB-106 PK Parameters

    Percentage of area under the curve from time of the last quantifiable concentration to infinity to area under the curve to infinity (AUC_extr%)

    Time frame: 29 days

  3. AB-106 PK Parameters

    Lambda_z, first-order rate constant associated with the terminal portion of the curve (λz)

    Time frame: 29 days

  4. AB-106 PK Parameters

    Terminal phase elimination half life (t1/2)

    Time frame: 29 days

  5. AB-106 PK Parameters

    Apparent total clearance (CL/F)

    Time frame: 29 days

  6. AB-106 PK Parameters

    Apparent volume of distribution (Vz/F)

    Time frame: 29 days

  7. Safety Assessment

    Adverse events (AEs)

    Time frame: 47 days

07

Study locations

1 site
  • Xuanwu Hospital of Capital Medical University
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Dec 2021, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2021
First posted
May 3, 2022
StartActual
Jul 19, 2021
Primary completionActual
Dec 3, 2021
CompletionActual
Dec 3, 2021
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05357820
Lead sponsor
Nuvation Bio Inc.
Responsible party
Sponsor
First posted
May 3, 2022
Start date
Jul 19, 2021
Primary completion
Dec 3, 2021
Completion
Dec 3, 2021
Last update
Nov 21, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Taletrectinib · Itraconazole · Rifampin

Start the discussion